2001
DOI: 10.1590/s0100-879x2001000900001
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Colorectal cancer is one of the most frequent malignancies in humans and an important cause of cancer death. Metastatic colorectal cancer remains incurable with available systemic therapeutic options. The most active cytotoxic drug against this malignancy, the antimetabolite 5-fluorouracil, was developed more than forty years ago, and as a single agent produces responses in only 10 to 15% of patients which in general last less than one year. Efforts to ameliorate these poor results resulted in the 5-fluorourac… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
15
0

Year Published

2003
2003
2022
2022

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 25 publications
(15 citation statements)
references
References 45 publications
0
15
0
Order By: Relevance
“…The combination therapy with 5-FU/LV and CPT-11 or oxaliplatin demonstrated to be more active than 5-FU/LV as a first-line treatment. Oxaliplatin and CPT-11 combined, or not, with other agents are also active in the second-line treatment of colorectal carcinoma [2,47]. Hence, resistance to current therapies still remains one of the major problems in the treatment of colon cancers.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The combination therapy with 5-FU/LV and CPT-11 or oxaliplatin demonstrated to be more active than 5-FU/LV as a first-line treatment. Oxaliplatin and CPT-11 combined, or not, with other agents are also active in the second-line treatment of colorectal carcinoma [2,47]. Hence, resistance to current therapies still remains one of the major problems in the treatment of colon cancers.…”
Section: Discussionmentioning
confidence: 99%
“…Several studies suggested that these agents may be synergistic in combination [1,2]. In fact, preclinical and clinical studies suggested that metastatic colon cancers do not generally manifest cross-resistance to these two agents when they are used serially [2][3][4].…”
Section: Introductionmentioning
confidence: 99%
“…Many studies were carried out to evaluate the combinations of antitumor drugs, for example interferon resulted in synergistic interactions with antitumor ruthenium complexes [65]. New 5-fluoracil analogues and folate antagonist, the inhibitor of topoisomerase I irinotecan and the third-generation platinum compound oxaliplatin [66][67][68] developed, based on distinct mechanism of cytotoxicity and resistance, as well as effective combination patterns show themselves to be very promising.…”
Section: B Cmentioning
confidence: 99%
“…Another approach to bypass resistance to this drug (and basically any drug) is to develop clever combinations in which one drug sometimes uses the resistance mechanism in order to be effective [10] . Therefore 5FU is often combined with cisplatin in the treatment of head & neck cancer, and with oxaliplatin in colon cancer (FOLFOX regimens) [11] . Novel combinations include bevacizumab which neutralizes the vascular endothelial growth factor [12] , and inhibits angiogenesis.…”
Section: What Is Special In the First Issue?mentioning
confidence: 99%